Reed Brent N, Rodgers Jo E, Sueta Carla A
Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA.
Heart Fail Clin. 2014 Oct;10(4):577-90. doi: 10.1016/j.hfc.2014.07.005. Epub 2014 Aug 13.
Polypharmacy, the use of 4 or more medications, is universal in patients with heart failure (HF). Evidence-based combination therapy is prescribed in patients with HF with reduced ejection fraction (HFrEF). Additionally, treatment of the high prevalence of comorbidities presents many therapeutic dilemmas. The use of nonprescription medications is common, adding further complexity to the medication therapy regimens of patients with HF. An approach for combining evidence-based therapies in patients with HFrEF is presented. Strategies for optimizing the management of common comorbidities in patients with HF are reviewed. Both prescription and nonprescription medications to avoid or use with caution are highlighted.
多重用药,即使用4种或更多药物,在心力衰竭(HF)患者中很普遍。射血分数降低的心力衰竭(HFrEF)患者需采用循证联合治疗。此外,合并症的高患病率治疗带来了许多治疗难题。非处方药的使用很常见,这进一步增加了HF患者药物治疗方案的复杂性。本文介绍了一种HFrEF患者循证治疗联合的方法。回顾了优化HF患者常见合并症管理的策略。强调了应避免或谨慎使用的处方药和非处方药。